ADC Therapeutics Stock Price, News & Analysis (NYSE:ADCT) $1.03 -0.08 (-7.21%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$0.97▼$1.0950-Day Range$0.47▼$1.1352-Week Range$0.36▼$5.75Volume411,786 shsAverage Volume478,315 shsMarket Capitalization$79.11 millionP/E RatioN/ADividend YieldN/APrice Target$5.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media ADC Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.29 Rating ScoreUpside/Downside256.0% Upside$3.67 Price TargetShort InterestBearish6.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.38) to ($1.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector514th out of 948 stocksPharmaceutical Preparations Industry224th out of 421 stocks 3.1 Analyst's Opinion Consensus RatingADC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.67, ADC Therapeutics has a forecasted upside of 256.0% from its current price of $1.03.Amount of Analyst CoverageADC Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.79% of the float of ADC Therapeutics has been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in ADC Therapeutics has recently decreased by 8.82%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADCT. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for ADC Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ADCT on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.40% of the stock of ADC Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.29% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for ADC Therapeutics are expected to grow in the coming year, from ($2.38) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADC Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ADC Therapeutics Stock (NYSE:ADCT)ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBDdimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Read More ADCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADCT Stock News HeadlinesDecember 1, 2023 | seekingalpha.comADC Therapeutics: Navigating A Swirling DrainNovember 26, 2023 | benzinga.comADC Therapeutics Stock (NYSE:ADCT) Dividends: History, Yield and DatesDecember 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 20, 2023 | markets.businessinsider.comAnalyst Expectations for ADC Therapeutics's FutureNovember 20, 2023 | finance.yahoo.comSobi to present new data at ASH 2023 Annual MeetingNovember 15, 2023 | finance.yahoo.comMyricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of DirectorsNovember 10, 2023 | msn.comTD Cowen Downgrades Adc Therapeutics (ADCT)November 8, 2023 | finance.yahoo.comADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call TranscriptDecember 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 8, 2023 | finance.yahoo.comQ3 2023 ADC Therapeutics SA Earnings CallNovember 7, 2023 | markets.businessinsider.comWhat Wall Street expects from ADC Therapeutics's earningsNovember 7, 2023 | finance.yahoo.comADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNovember 7, 2023 | finance.yahoo.comADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing StandardsNovember 7, 2023 | finance.yahoo.comADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue EstimatesNovember 5, 2023 | morningstar.comADC Therapeutics SA ADCTNovember 2, 2023 | finance.yahoo.comPuma Biotech (PBYI) Tops Q3 Earnings EstimatesNovember 2, 2023 | finance.yahoo.comADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual MeetingOctober 31, 2023 | finance.yahoo.comADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseOctober 24, 2023 | finance.yahoo.comADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023October 9, 2023 | benzinga.comAntibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight PartnersOctober 4, 2023 | finance.yahoo.comMyricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSOSeptember 5, 2023 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics to Participate in September Investor ConferencesSeptember 5, 2023 | finance.yahoo.comADC Therapeutics to Participate in September Investor ConferencesAugust 30, 2023 | finance.yahoo.comADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)August 14, 2023 | finance.yahoo.comAtreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%August 11, 2023 | finance.yahoo.comCatalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook RaisedAugust 10, 2023 | msn.comRBC Capital Maintains Adc Therapeutics (ADCT) Outperform RecommendationSee More Headlines Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ADCT CUSIPN/A CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees317Year FoundedN/APrice Target and Rating Average Stock Price Target$3.67 High Stock Price Target$6.00 Low Stock Price Target$2.00 Potential Upside/Downside+458.3%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-155,800,000.00 Net Margins-145.64% Pretax Margin-148.08% Return on Equity-1,121.94% Return on Assets-36.23% Debt Debt-to-Equity Ratio2.57 Current Ratio4.80 Quick Ratio4.51 Sales & Book Value Annual Sales$122.57 million Price / Sales0.65 Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book0.89Miscellaneous Outstanding Shares76,810,000Free Float49,619,000Market Cap$79.11 million OptionableNot Optionable Beta1.24 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Ameet Mallik M.B.A. (Age 50)M.S., CEO & Director Comp: $819.74kMr. Jose I. Carmona M.B.A. (Age 51)Chief Financial Officer Dr. Patrick van Berkel Ph.D. (Age 55)Chief Scientific Officer Dr. Michael Mulkerrin Ph.D. (Age 68)Chief Technical Operations Officer Amanda HamiltonInvestor Relations OfficerMs. Susan Romanus (Age 58)Chief Compliance & Quality Officer Mr. Peter J. Graham Esq. (Age 56)Chief Legal Officer Ms. Kimberly Pope (Age 56)Senior VP & Chief People Officer Ms. Kristen Harrington-Smith (Age 50)Chief Commercial Officer Dr. Mohamed Zaki M.D. (Age 58)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsIO BiotechNASDAQ:IOBTEagle PharmaceuticalsNASDAQ:EGRXViveon Health AcquisitionNYSE:VHAQShattuck LabsNASDAQ:STTKRelmada TherapeuticsNASDAQ:RLMDView All CompetitorsInstitutional OwnershipRedmile Group LLCBought 128,110 shares on 11/15/2023Ownership: 18.459%Affinity Asset Advisors LLCBought 500,000 shares on 11/15/2023Ownership: 1.432%Acadian Asset Management LLCBought 134,186 shares on 11/13/2023Ownership: 0.203%View All Institutional Transactions ADCT Stock Analysis - Frequently Asked Questions Should I buy or sell ADC Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares. View ADCT analyst ratings or view top-rated stocks. What is ADC Therapeutics' stock price target for 2024? 6 analysts have issued 12 month price targets for ADC Therapeutics' stock. Their ADCT share price targets range from $2.00 to $6.00. On average, they predict the company's stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 256.0% from the stock's current price. View analysts price targets for ADCT or view top-rated stocks among Wall Street analysts. How have ADCT shares performed in 2023? ADC Therapeutics' stock was trading at $3.84 at the beginning of 2023. Since then, ADCT shares have decreased by 73.2% and is now trading at $1.03. View the best growth stocks for 2023 here. Are investors shorting ADC Therapeutics? ADC Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 3,620,000 shares, a decline of 8.8% from the October 31st total of 3,970,000 shares. Based on an average trading volume of 297,800 shares, the short-interest ratio is presently 12.2 days. Approximately 6.8% of the shares of the stock are short sold. View ADC Therapeutics' Short Interest. When is ADC Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our ADCT earnings forecast. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.03. The business earned $14.49 million during the quarter, compared to the consensus estimate of $14.57 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 1,121.94% and a negative net margin of 145.64%. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX). When did ADC Therapeutics IPO? (ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO. Who are ADC Therapeutics' major shareholders? ADC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (18.46%), Affinity Asset Advisors LLC (1.43%), Acadian Asset Management LLC (0.20%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:ADCT) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.